EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Field evaluation of nanopore targeted next-generation sequencing to predict drug-resistant tuberculosis from native sputum in South Africa and Zambia

Tiana C Schwab iD, Lavania Joseph, Andrew Moono, Pauline C Göller, Mamello Motsei, Guy Muula, Denise Evans, Stefan Neuenschwander, Gunar Günther iD, Carolyn Bolton, Peter M Keller, Alban Ramette und 4 weitere

Journal of Clinical Microbiology · 12.03.2025 · 63 (3)

DOI: 10.1128/jcm.01390-24 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 12.03.2025. Verfasst von Tiana C Schwab und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Sputum, Mycobacterium tuberculosis, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapid and comprehensive drug susceptibility testing (DST) is essential for diagnosing and treating drug-resistant tuberculosis effectively, and next-generation sequencing can be an effective genotypic DST method. We implemented and evaluated the performance of a nanopore targeted sequencing assay, called the Tuberculosis Drug Resistance Test (TBDR, Oxford Nanopore Diagnostics, Ltd., United Kingdom), which predicts drug resistance to 16 TB drugs, at a South African reference laboratory and a district diagnostic laboratory in Zambia. We compared the sequencing success rates between unprocessed and decontaminated sputum samples and determined the diagnostic accuracy against local DST (Xpert MTB/RIF Ultra, Xpert MTB/XDR, and BD BACTEC MGIT phenotypic DST). We prospectively sequenced 236 samples and have 148 samples with sequencing results from unprocessed and decontaminated sputum. We obtained successful sequencing results from 66.4% (94/148) unprocessed sputum samples and 75% (111/148) decontaminated samples. Sequencing success rates at the two sites differed, with 50.7% (36/71) successful sequencing results from unprocessed sputum in Zambia and 75.3% (58/77) in South Africa. Samples with “low” bacterial load, measured by Xpert MTB/RIF Ultra, tended to produce fewer successful sequencing results. TBDR sequencing predicted resistances in 48 samples, detecting resistance for rifampicin ( n = 41) and isoniazid ( n = 20), as well as 10 second-line drugs ( n = 15). Sensitivity was variable compared to phenotypic DST, ranging from 33 (ethionamide) to 94% (rifampicin), while specificity remained above 90% for all drugs, except clofazimine. The TBDR assay can provide rapid, comprehensive genotypic DST. Technical and operational challenges need to be addressed for its broader implementation in high tuberculosis-burden settings. IMPORTANCE This study illustrates the use of the Tuberculosis Drug Resistance Test (TBDR, Oxford Nanopore Diagnostics, Ltd., United Kingdom) as a rapid drug susceptibility testing (DST) approach for diagnosing drug-resistant TB in the high TB-burden countries of South Africa and Zambia. The TBDR assay predicts resistance to 16 TB drugs, including first- and second-line treatments. By implementing the TBDR assay in a national reference laboratory in South Africa and a district diagnostic laboratory in Zambia, we demonstrate how this technology can provide faster diagnostic results (days) compared to traditional phenotypic DST methods (~2 months), with adequate sensitivity. Missed resistances compared to phenotypic DST indicate that technical improvements are needed. Successful sequencing from unprocessed and decontaminated sputum samples at different sites suggests feasibility in diverse settings, though operational challenges remain. Implementing this rapid, comprehensive DST approach could enhance drug-resistant tuberculosis diagnosis and treatment, ultimately improving patient outcomes and helping to combat tuberculosis in high-burden regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, Multidrug-ResistantSputumMycobacterium tuberculosisHigh-Throughput Nucleotide SequencingNanoporesNanopore SequencingHumansSouth AfricaZambiaMicrobial Sensitivity TestsAntitubercular AgentsProspective StudiesSensitivity and Specificity

Stichwörter der Autor:innen

implementationlow- and middle-income countriesnanopore sequencingnext-generation sequencingresistance predictiontuberculosis

Substanzen

Antitubercular Agents

Autor:innen und Institutionen

  • Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Centre for Tuberculosis, National & WHO Supranational TB Reference Laboratory, a division of the National Health Laboratory Services, National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Center for Infectious Disease Research in Zambia, Lusaka, Zambia.
  • Institute of Medical Microbiology, University of Zürich, Zürich, Switzerland.
  • Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Institute for Infectious Diseases, University of Bern Institute for Infectious Diseases, Bern, Switzerland.

ORCID-Profile: Tiana C Schwab, Gunar Günther, Matthias Egger, Lukas Fenner

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

Zitieren

APA

Schwab, T. C., Joseph, L., Moono, A., Göller, P. C., Motsei, M., Muula, G., Evans, D., Neuenschwander, S., Günther, G., Bolton, C., Keller, P. M., Ramette, A., Egger, M., Omar, S. V., Fenner, L., & IeDEA Southern Africa (IeDEA-SA) (2025). Field evaluation of nanopore targeted next-generation sequencing to predict drug-resistant tuberculosis from native sputum in South Africa and Zambia. Journal of Clinical Microbiology, 63(3). https://doi.org/10.1128/jcm.01390-24

Vancouver

Schwab TC, Joseph L, Moono A, Göller PC, Motsei M, Muula G, et al. Field evaluation of nanopore targeted next-generation sequencing to predict drug-resistant tuberculosis from native sputum in South Africa and Zambia. Journal of Clinical Microbiology. 2025;63(3). doi:10.1128/jcm.01390-24

BibTeX
@article{Schwab2025,
  author = {Schwab, Tiana C and Joseph, Lavania and Moono, Andrew and Göller, Pauline C and Motsei, Mamello and Muula, Guy and Evans, Denise and Neuenschwander, Stefan and Günther, Gunar and Bolton, Carolyn and Keller, Peter M and Ramette, Alban and Egger, Matthias and Omar, Shaheed V and Fenner, Lukas and IeDEA Southern Africa (IeDEA-SA), IeDEA Southern Africa (IeDEA-SA)},
  title = {Field evaluation of nanopore targeted next-generation sequencing to predict drug-resistant tuberculosis from native sputum in South Africa and Zambia},
  journal = {Journal of Clinical Microbiology},
  year = {2025},
  volume = {63},
  number = {3},
  doi = {10.1128/jcm.01390-24}
}
Kostenlos starten →